Results 51 to 60 of about 390,088 (309)

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

Clinical Ophthalmology, 2023
Tomoko Miyakubo, Ryo Mukai, Hidetaka Matsumoto, Masahiro Morimoto, Maki Takahashi, Kazuki Nagai, Kosuke Nakamura, Junki Hoshino, Hideo Akiyama Department of Ophthalmology, Gunma University, Graduate School of Medicine, Maebashi, Gunma ...
Miyakubo T, Mukai R, Matsumoto H, Morimoto M, Takahashi M, Nagai K, Nakamura K, Hoshino J, Akiyama H   +8 more
doaj  

Age, Initial Central Retinal Thickness, and OCT Biomarkers Have an Influence on the Outcome of Diabetic Macular Edema Treated With Ranibizumab– Tri-center 12-Month Treat-and-Extend Study

Frontiers in Medicine, 2021
Objective: We report the tri-center 1-year outcomes of a treat-and-extend (T&E) regimen in four-week intervals with ranibizumab for diabetic macular edema (DME).Methods: In this retrospective study, all eyes received 3 monthly loading injections of 0.
Chun-Ting Lai, Yi-Ting Hsieh, Chun-Ju Lin, Chun-Ju Lin, Chun-Ju Lin, Jia-Kang Wang, Jia-Kang Wang, Chih-Ying Lin, Chih-Ying Lin, Ning-Yi Hsia, Ning-Yi Hsia, Henry Bair, Huan-Sheng Chen, Chiung-Yi Chiu, Shao-Wei Weng   +14 more
doaj   +1 more source

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Ophthalmology (Rochester, Minn.), 2019
PURPOSE To test the hypothesis that tolerating some subretinal fluid (SRF) in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab using a treat-and-extend (T&E) regimen can achieve similar visual acuity (VA ...
R. Guymer, C. Markey, I. McAllister, M. Gillies, A. Hunyor, J. Arnold   +5 more
semanticscholar   +1 more source

Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease

JAMA ophthalmology, 2020
Key Points Question Does a treat-and-extend approach with potentially less frequent anti-vascular endothelial growth factor injections and visits provide visual outcomes not worse than monthly ranibizumab injections in patients with neovascular acute ...
P. Kertes, I. Galić, M. Greve, G. Williams, Jason Baker, M. Lahaie, T. Sheidow   +6 more
semanticscholar   +1 more source

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2021
Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as treatment of neovascular age-related macular degeneration (nAMD), the (economic) burden on the healthcare system is considerable. A treat-and-extend (T&E) regimen
S. Quist, De L. A. Jong, F. van Asten, P. Knoester, M. J. Postma, R. Freriks   +5 more
semanticscholar   +1 more source

Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration

Eye, 2020
Objectives This report aims to provide clear recommendations and practical guidance from a panel of UK retinal experts on an aflibercept treat-and-extend (T&E) pathway that can be implemented in clinical practice.
A. Ross, L. Downey, H. Devonport, R. Gale, Ajay Kotagiri, S. Mahmood, H. Mehta, N. Narendran, P. Patel, N. Parmar, Nitin Jain   +10 more
semanticscholar   +1 more source

Myasthenia Gravis with Membranous Nephropathy, Successfully Treated with Extended Total Thymectomy.

Internal Medicine, 2000
A 46-year-old woman showed proteinuria and hematuria after left blepharoptosis, and revealed a histopathology of membranous nephropathy (MN) at renal biopsy. She was diagnosed as having myasthenia gravis (MG) because of a positive edrophonium test and anti-acetylcholine receptor (AchR) antibodies in serum.
MATSUDA, Masayuki, MIKI, Jun, TABATA, Ken-ichi, IKEZOE, Masaya, NISHIZAWA, Nobuhiro, ISHIGAME, Hiroki   +5 more
openaire   +3 more sources

Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration

, 2014
PURPOSE: To report 24-month outcomes of anti-vascular endothelial growth factor (VEGF) therapy for treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) using a treat and extend treatment regimen in routine clinical practice ...
Morlet, Nigel, Simpson, Judy M, Gillies, Mark C, Barthelmes, D., Essex, R., Campain, A., Arnold, Jennifer J, Guymer, R., Gillies, M., Campain, Anna, Essex, Rohan W, Hunyor, Alex P, Simpson, J., McAllister, Ian L, McAllister, I., Arnold, J., Guymer, Robyn H, Hunyor, A., Barthelmes, Daniel   +18 more
core   +2 more sources

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration

Российский офтальмологический журнал, 2020
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenesis inhibitors in the treat-and-extend regimen in patients with the “wet” form of age-related macular degeneration (wAMD). Materials and methods.
S. V. Nedogoda, A. S. Salasyuk, E. V. Bobykin, I. N. Barykina, V. O. Smirnova, E. A. Popova   +5 more
doaj   +1 more source

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan

BMC Ophthalmology, 2022
The management of neovascular age-related macular degeneration (nAMD) has taken a major stride forward with the advent of anti-VEGF agents. The treat-and-extend (T&E) approach is a refined management strategy, tailoring to the individual patient’s ...
Cheng-Kuo Cheng, Shih-Jen Chen, Jiann-Torng Chen, Lee-Jen Chen, San-Ni Chen, Wen-Lu Chen, Sheng-Min Hsu, Chien-Hsiung Lai, Shwu-Jiuan Sheu, Pei-Chang Wu, Wei-Chi Wu, Wen-Chuan Wu, Chung-May Yang, Ling Yeung, Ta-Ching Chen, Chang-Hao Yang   +15 more
doaj   +1 more source